Cyclerion Therapeutics, Inc. - Common Stock (CYCN)

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. Upon closing of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company.

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the transaction, the combined company plans to operate under the name Korsana Biosciences, Inc. and trade on Nasdaq under the ticker symbol “KRSA.”

–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)–

Synergy CHC Corp. (NASDAQ: SNYR) is gaining renewed investor attention as its FOCUSfactor® functional beverage platform scales rapidly through the Company’s already-established retail ecosystem—built on the strength of its 25-year FOCUSfactor® brain health supplement legacy . By leveraging long-standing national distribution relationships, Synergy is accelerating beverage adoption without the execution risk typically associated with launching a new consumer brand.This beverage expansion underpins Roth Capital Partners’ Buy rating and 12-month $7 price target on SNYR. Roth projects revenues could grow from approximately $35.4 million in 2025 to nearly $55 million in 2026, driven largely by beverage penetration layered onto Synergy’s existing retail and wholesale channels.

– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer –

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Discover the stocks with unexpected trading volume in today's session on the US markets.

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Cycurion, Inc (NASDAQ: CYCU) secures contract for $1 million to modernize federal government's critical communication network over 24-36 months.

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.

In today's session, these stocks are experiencing unusual volume.